{"acquisitions":[],"changes":[],"country":"US","description":"Kailera Therapeutics develops next-generation GLP-1 and incretin drugs for obesity and metabolic disease, in-licensing assets from Hansoh Pharma. Patients with obesity and type 2 diabetes are the eventual customer base; clinicians and payers are buyers. Kailera advances clinical trials of KAI-9531 plus follow-on candidates with multi-receptor agonism.","domain":"kailerarx.com","employees":null,"founded":2024,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"unknown","industrySources":[],"investors":[],"lat":42.376238,"lng":-71.235564,"location":"Waltham MA","multiples":[],"name":"Kailera Therapeutics","people":[],"revenues":[],"rounds":[{"amountQuarantined":false,"amountUsd":600000000,"connectionsAmong":[],"currency":"USD","date":"2025-10-01","investments":[],"investors":[],"leadInvestor":null,"leadInvestors":[],"people":[],"slug":"kailerarx-com-2025-10-01-series-b","source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},"status":"attributed","type":"series-b","url":null}],"slug":"kailerarx-com","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-02","status":"attributed","url":null},{"fact":"existence","publisher":"kailerarx.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://kailerarx.com"},{"fact":"description","publisher":"kailerarx.com","retrievedAt":"2026-05-02","status":"self-reported","url":"https://kailerarx.com"}],"stage":"series-b+","stockCard":{"asOf":"2026-11-09","facts":[],"generatedAt":"2026-11-09","state":"insufficient-evidence","tldr":[]},"techStack":[],"totalRaisedUsd":900000000,"traction":[],"updatedAt":"2026-05-02","valuations":[]}